

1. Gunness-Hey M and Hock JM (1984): Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. *Metab Bone & Rel Dis* 5:177-181.
2. Lorenzo JA; Sousa SL; Fonseca J; Hock JM and Medlock ES (1986): Colony stimulating factors regulate the development of multinucleated osteoclasts from recently replicated cells in vitro. *J Clin Invest* 80:160-164.
3. Hock JM; Centrella M and Canalis E (1988): Insulin-like growth factor I (IGF-I) has independent effects on bone matrix formation and cell replication. *Endocrinology* 122:254-260.
4. Gunness-Hey M and Hock JM (1990): Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. *Bone* 10:447-452.
5. Jüppner H; Abou-Samra AB; Freeman MW; Schipani E; Hock J; Kong X; Richards J; Kolakowski LF; Potts Jr JT; Kronenberg HM, Segre GV (1991) Expression cloning of a PTH/PTHrP receptor: a novel G protein-linked receptor. *Science* 254:1024-26.
6. Hock JM and Gera I (1992): Effects of continuous and intermittent administration and of inhibition of resorption on the anabolic response of bone to parathyroid hormone. *J Bone & Min Res* 7:65-72.
7. Hock JM and Canalis E (1994): Platelet-derived growth factor enhances bone cell replication but not differentiated function of osteoblasts. *Endocrinology*, 134:1423-1428
8. Onyia J; Bidwell J and Hock JM (1994): In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. *Bone* 17:479-84.
9. Alvarez M; Long H; Onyia J; Hock JM; Xu W and Bidwell J (1997): Rat osteoblast and osteosarcoma nuclear matrix proteins bind with sequence specificity to the rat type I collagen promoter. *Endocrinology* 138:482-489.
10. Turner CH, Owan I, Alvey T, Hulman J, Hock JM. 1998. Recruitment and proliferative responses of osteoblasts after mechanical loading in vivo, determined using sustained-release bromodeoxyuridine. *Bone* 22:463-469.
11. Hirano T, Burr DB, Turner CH, Sato M, Cain R, Hock JM. 1999. Effects of parathyroid hormone on cortical and trabecular bone mass, strength & histomorphometry of spine and long bones of rabbits *J Bone Min Res.*14:536-545
12. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM, 2000. Intermittently administered hPTH (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. *J Bone & Min Res* 16:157-165.
13. Feister H, Onyia JE, Miles RR, Yang X, Galvin R, Hock JM, Bidwell JP 2000 The expression of the nuclear matrix proteins NuMA, topoisomerase II-alpha & -beta in bone & osseous cell culture: regulation by PTH *Bone* 26:227-234.
14. Stanislaus, D, Yang X, Liang JD, Wolfe J, Cain RL, Onyia JE, Falla N, Marder P, Bidwell JP, Hock JM. 2000. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone fragment, hPTH 1-34. *Bone* 27:209-218.
15. Stanislaus, D., V. Devanarayan, J. Hock, 2000. In vivo comparison of AP-1 gene activation in response to hPTH 1-34 and hPTH 1-84 in the distal femur metaphyses of young mice. *Bone* 27:819-826.
16. Hock JM. 2001. Anabolic actions of PTH in the skeletons of animals. *J Musculoskel Neuron Interact* 2:33-47.
17. Hock JM, Krishnan V, Onyia JE, Bidwell JP, Milas J, Stanislaus D. 2001. Apoptosis and the osteoblast axis of bone turnover. (Review). *J Bone Miner Res.*16:975-984.
18. Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R. 2001. Treatment with human parathyroid hormone 91-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (*Macaca fascicularis*). *Bone*. 28:150-159.
19. Hirano T. Burr DB. Cain RL. Hock JM. 2000. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). *Calcif Tiss Int.* 66:456-60.
20. Frolik CA, Black EC, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock J. 2003. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. *Bone* 33:372-379.
21. Sato M, Ma YL, Hock JM, Westmore MS, Vahle J, Villanueva A, C.H. Turner, CH. 2002. Optimal Skeletal Efficacy With PTH in Rats Is Not Obtained with Long-term Treatment. *J Pharmacol Exptl Therapeutics.* 302:304-313
22. Gorlick R, et al. 2003. Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development - Meeting Summary. *Clin Cancer Res.*9:5442-5553.
23. Allen MR, Hock, JM, Burr DB 2004 Periosteum: potential target for osteoporosis intervention *Bone* 35: 1003-1012.
24. Yu X, Chen S, Potter OP, Murthy S, Pulcini J, Ohashi N, Everett ET, Ingram D, Clapp WD, Hock JM. 2005. Neurofibromin and its inactivation of ras as prerequisites for osteoblast functioning. *Bone*. 36:793-802
25. Yao W Zhong J Rosen CJ Hock JM Lee WH 2005IGF-I & Postnatal Growth of Weaver Mutant Mice *Endocrine*26:117-125.
26. Yu X. Milas J. Watanabe N. Rao N. Murthy S. Potter OL. Wenning MJ. Clapp WD. Hock JM. 2006 Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone. *Calcif Tiss Internat.* 78:162-70.

27. Prahalad A, Hickey RJ, Huang J, Murthy S, Winata T, Dobrolecki L, Hock JM. 2006. Protein profiling identifies molecular predictors of parathyroid hormone response. *Proteomics*. 6:3482-93.
28. Yang J, Murthy S, Winata T, Werner S, Abe M, Hock JM. 2006. Recql4 haploinsufficiency in mice leads to defects in osteoblast progenitors: implications for low bone mass phenotype. *Bio Biophys Res Comm*. 344:346-52.
29. Werner SR, Prahalad AK, Yang J, Hock JM. 2006. RECQL4-deficient cells are hypersensitive to oxidative stress/damage: Insights for osteosarcoma prevalence and heterogeneity in Rothmund-Thomson syndrome. *BBRC*. 345:403-9.
30. Yang FC, Chen S, Ribking AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW. 2006. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficiency osteoclast function. *J Clin Invest* 116:2880-2891
31. Jimenez JL, Lyon T, Nowinski G, Balazsy J, Goulet JA, Wolff S, Sferra TA, Armstrong RD, Hock JM. 2007. Stem and progenitor cell therapy for management of refractory long bone non-unions: a multi-center clinical feasibility study. *J Bone Joint Surgery (US)*. Submitted 04/07.